CN105267696A - 一种用于肾阴虚型慢性肾盂肾炎的中药丸剂及制备方法 - Google Patents
一种用于肾阴虚型慢性肾盂肾炎的中药丸剂及制备方法 Download PDFInfo
- Publication number
- CN105267696A CN105267696A CN201510814981.8A CN201510814981A CN105267696A CN 105267696 A CN105267696 A CN 105267696A CN 201510814981 A CN201510814981 A CN 201510814981A CN 105267696 A CN105267696 A CN 105267696A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- yin
- chinese medicine
- medicine pill
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 206010037601 Pyelonephritis chronic Diseases 0.000 title claims abstract description 27
- 201000006368 chronic pyelonephritis Diseases 0.000 title claims abstract description 27
- 208000031971 Yin Deficiency Diseases 0.000 title claims abstract description 26
- 239000006187 pill Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 210000003734 kidney Anatomy 0.000 claims abstract description 47
- 210000000582 semen Anatomy 0.000 claims abstract description 18
- 241000722953 Akebia Species 0.000 claims abstract 4
- 244000286838 Eclipta prostrata Species 0.000 claims abstract 4
- 241000025505 Pyrrosia Species 0.000 claims abstract 4
- 239000000843 powder Substances 0.000 claims description 27
- 238000007654 immersion Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 16
- 238000010410 dusting Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 11
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 244000025254 Cannabis sativa Species 0.000 claims description 8
- 241000245032 Trillium Species 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 6
- 230000008020 evaporation Effects 0.000 claims description 6
- 235000019991 rice wine Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 239000003205 fragrance Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 235000014101 wine Nutrition 0.000 claims description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 claims 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims 3
- 241000202807 Glycyrrhiza Species 0.000 claims 3
- 241000612166 Lysimachia Species 0.000 claims 3
- 210000004369 blood Anatomy 0.000 abstract description 37
- 239000008280 blood Substances 0.000 abstract description 37
- 230000001737 promoting effect Effects 0.000 abstract description 34
- 210000004185 liver Anatomy 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 21
- 208000004880 Polyuria Diseases 0.000 abstract description 20
- 201000010099 disease Diseases 0.000 abstract description 20
- 230000035619 diuresis Effects 0.000 abstract description 20
- 238000011282 treatment Methods 0.000 abstract description 15
- 230000009471 action Effects 0.000 abstract description 5
- 230000002411 adverse Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 238000012795 verification Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000000295 complement effect Effects 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 3
- 241000220457 Crotalaria Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 240000007420 Hypericum patulum Species 0.000 abstract 1
- 235000002710 Ilex cornuta Nutrition 0.000 abstract 1
- 241001310146 Ilex cornuta Species 0.000 abstract 1
- 241000212322 Levisticum officinale Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 241001247783 Meconopsis Species 0.000 abstract 1
- 241000968145 Meconopsis wallichii Species 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 abstract 1
- 235000011096 Papaver Nutrition 0.000 abstract 1
- 240000001090 Papaver somniferum Species 0.000 abstract 1
- 241000519406 Paphiopedilum Species 0.000 abstract 1
- 241000764065 Persicaria capitata Species 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 241000756042 Polygonatum Species 0.000 abstract 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 abstract 1
- 241000722273 Saururus cernuus Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000007215 black sesame Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 239000001645 levisticum officinale Substances 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 description 18
- 206010011224 Cough Diseases 0.000 description 17
- 230000008961 swelling Effects 0.000 description 16
- 230000007812 deficiency Effects 0.000 description 13
- 231100000614 poison Toxicity 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 12
- 210000001624 hip Anatomy 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 239000003440 toxic substance Substances 0.000 description 9
- 206010007247 Carbuncle Diseases 0.000 description 8
- 208000002173 dizziness Diseases 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 230000008736 traumatic injury Effects 0.000 description 8
- 241000411851 herbal medicine Species 0.000 description 7
- 230000027939 micturition Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 210000003932 urinary bladder Anatomy 0.000 description 7
- 208000009205 Tinnitus Diseases 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 208000001848 dysentery Diseases 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000001047 pyretic effect Effects 0.000 description 6
- 231100000886 tinnitus Toxicity 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010023126 Jaundice Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 201000008383 nephritis Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 206010013781 dry mouth Diseases 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 230000003014 reinforcing effect Effects 0.000 description 4
- 239000002435 venom Substances 0.000 description 4
- 210000001048 venom Anatomy 0.000 description 4
- 231100000611 venom Toxicity 0.000 description 4
- 230000002087 whitening effect Effects 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010011878 Deafness Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 206010044302 Tracheitis Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 208000004396 mastitis Diseases 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 206010044008 tonsillitis Diseases 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- MJPMPMZXJIZPRE-UHFFFAOYSA-N 3-butyl-5,6,7,7a-tetrahydro-3h-2-benzofuran-1-one Chemical compound C1CCC=C2C(CCCC)OC(=O)C21 MJPMPMZXJIZPRE-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010033425 Pain in extremity Diseases 0.000 description 2
- 206010034038 Parotitis Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000000244 kidney pelvis Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 208000030208 low-grade fever Diseases 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010009168 Chyluria Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010058117 Ocular icterus Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229950009125 cynarine Drugs 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 208000009189 tinea favosa Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于肾阴虚型慢性肾盂肾炎的中药丸剂及制备方法,属中药领域。本发明药物有效成分的原料组成为:凤尾草、黄精、枸骨叶、白紫草、石莽草、麦冬、金钱草、墨旱莲、响铃草、石斛、三白草、山萸肉、车前草、石韦、斑叶兰、木通根、黑芝麻、川芎、金丝梅、决明子、女贞子、甘草、山莴笋、五味子。本发明选用药材的药性相适相辅,针对病因对症下药,有补益肝肾、养阴益气、行气活血、清热利湿、解毒消肿之功效,吸收效果好,疗效显著,无毒副作用及临床不良反应,经临床验证对肝肾阴虚型慢性肾盂肾炎治愈率较高,具有很好的临床推广应用前景。
Description
所属技术领域
本发明涉及中药领域,尤其涉及一种用于肾阴虚型慢性肾盂肾炎的中药丸剂及制备方法。
背景技术
慢性肾盂肾炎是细菌感染肾脏引起的慢性炎症,病变主要侵犯肾间质和肾盂、肾盏组织。由于炎症的持续进行或反复发生导致肾间质、肾盂、肾盏的损害,形成疤痕,以至肾发生萎缩和出现功能障碍。平时病人可能仅有腰酸和(或)低热,可没有明显的尿路感染的尿痛,尿频和尿急症状,其主要表现是夜尿增多及尿中有少量白细胞和蛋白等。
在近几年来,慢性肾盂肾炎一直都是发病率较高的疾病,给患者朋友们在生活之中也都带来了很大的痛苦,并且通常发生于儿童和女性朋友身上。现代医学对本病的治疗主要应用抗生素以抗菌消炎,对发作时控制症状有较好的疗效,但由于抗生素对肾脏及全身的毒副作用以及耐药性的影响,复发率较高,治疗效果并不理想。
慢性肾盂肾炎基本上属中医“淋证”、“腰痛”范畴,其基本病机为正虚邪恋,虚实夹杂,病因多为湿热、邪毒,或人之脏腑阴阳气血亏损,病位在肾与膀胱,但与肝、脾关系密切。由于病程缠绵日久,伤及人之脏腑阴阳气血,故多从气阴两虚,脾肾两虚,肝肾阴虚及肾阳虚等来进行辨析。本发明中药主要针对肝肾阴虚型慢性肾盂肾炎进行治疗,本病主要症状为:尿频,尿急,尿道灼热,尿淋漓不尽,低热,手足心热,头晕耳鸣,腰膝酸软,甚至盗汗,梦遗或是月经不调。舌红少苔,脉沉细。本发明认为本型疾病其病机特点为本虚标实,本虚主要是肝肾阴虚,标实是膀胱之湿热,并夹杂毒邪、瘀血等,故本发明中药根据病因对症下药,具有补益肝肾、养阴益气、行气活血、清热利湿、解毒消肿之功效,标本兼治,可调节机体免疫,改善肝肾功能,吸收效果好,疗效显著,无毒副作用及临床不良反应,经临床验证对肝肾阴虚型慢性肾盂肾炎治愈率较高。
发明内容
本发明提供了一种用于肾阴虚型慢性肾盂肾炎的中药丸剂及制备方法,具有补益肝肾、养阴益气、行气活血、清热利湿、解毒消肿之功效,治病求源标本兼治,对肝肾阴虚型慢性肾盂肾炎具有很好的疗效。
为实现上述目的,本发明的技术方案实施如下:
一种用于肾阴虚型慢性肾盂肾炎的中药丸剂,制成所述药物有效成分的原料组成及重量份数为:
制成所述药物有效成分的原料组成及重量份数为:
制成所述药物有效成分的原料组成及重量份数为:
一种用于肾阴虚型慢性肾盂肾炎的中药丸剂的制备方法,包括以下工艺步骤:
(1)将凤尾草、黄精、白紫草、石莽草、麦冬、墨旱莲、响铃草、石斛、三白草、山萸肉、车前草、石韦、黑芝麻、金丝梅、女贞子、山莴笋洗净、晾干后混合均匀,放入容器中,在容器中加入6~8倍量的水,加热煮沸2~3小时,冷却后取浸液;在剩余的药渣中再加入4~6倍量的水,加热煮沸1~2小时,冷却后取浸液;合并两次所得浸液,加热,蒸发浓缩为相对密度1.15~1.25的稠膏,备用;
(2)将枸骨叶、金钱草、斑叶兰、木通根放入容器中,加入3~5倍量的绍兴黄酒,煮沸后放凉,继续浸泡3~5小时,取浸液;在剩余的药渣中再加入2~4倍量的绍兴黄酒,煮沸后放晾,继续浸泡2~4小时,取浸液;合并两次所得浸液,加蒸蒸发浓缩为相对密度1.10~1.20的稠膏,备用;
(3)取川芎片用黄酒喷洒均匀,稍闷,置锅内炒至微焦为度,取出放凉,粉碎研末,过100目细筛,得细粉,备用;
(4)取净决明子,置锅内炒至微有香气,取出,放凉,粉碎研末,过100目细筛,得细粉,备用;
(5)取净甘草片,加入炼熟的蜂蜜与少许开水,拌匀后稍闷,置炒制容器内,文火炒至黄色至深黄色,不粘手时取出,放凉,粉碎研末,过100目细筛,得细粉,备用;
(6)将五味子粉碎后研末,过100目细筛,得细粉,备用;
(7)将步骤(1)、步骤(2)所得的稠膏,与步骤(3)、步骤(4)、步骤(5)、步骤(6)中所得的细粉混合,加入炼蜜搅拌均匀后,制备为每粒3g的药丸。
本发明所用中药的药性如下:
凤尾草:味淡;微苦;性寒。归大肠;心;肝经。清热利湿;凉血止血;消肿解毒。主治痢疾;泄泻;淋浊;带下;黄疸;疔疮肿毒;喉痹乳蛾;淋巴结核;腮腺炎;乳腺炎;高热抽搐;蛇虫咬伤;吐血;衄血;尿血;便血;外伤出血。《分类草药性》:治一切热毒,消肿,清火。治痈疮,乳痈,淋症。
黄精:味甘;性平。入脾;肺;肾经。养阴润肺;补脾益气;滋肾填精。主治阴虚劳嗽;肺燥咳嗽;脾虚乏力;食少口干;消渴;肾亏腰膝酸软;阳痿遗精;耳鸣目暗;须发早白;体虚羸瘦;风癞癣疾。《本草逢原》载:“宽中益气,使五藏调和,肌肉充盛,骨髓强坚,皆是补阴之功。”现代医学研究证实,黄精对肾上腺素引起的血糖升高有显著的抑制作用,对常见致病真菌有不同程度的抑制作用,升高肝脏超氧化物歧化酶活性,降低心肌脂褐质含量降低,增强对缺氧的耐受力,此外还有抗病毒功效。
枸骨叶:味苦;性凉。入肝;肾经。清虚热;益肝肾;祛风湿。主治阴虚劳热;咳嗽咯血;头晕目眩;腰膝酸软;风湿痹痛;白癜风。《本草经疏》载:“此药直入足少阴经,补养阴气,则痰火自消,如釜底抽薪之意出。兼能散风毒恶疮。”现代医学研究证实,枸骨叶能增加冠脉流量,增强心肌收缩力,所含的二咖啡酰喹宁酸对前列腺环素有较显著的促进释放作用。
白紫草:味苦;微甘;性微寒。归肺;胃经。养阴清热;利湿解毒;散瘀消肿。主治虚瘤发热;小便淋涩;痈肿疮毒;走马牙疳;跌打损伤。《滇南本草》:滋养真阴,调血除热。退诸痨热,利小便,治热淋膏淋。
石莽草:味苦;辛;性凉。清热利湿;活血止痛。主治痢疾;肾盂肾炎;膀胱炎;尿路结石;风湿痛;跌打损伤;痄腮;疮疡;湿疹。《云南中草药》:清热利尿,通淋。
麦冬:味甘;微苦;性微寒。归心;肺;胃经。养阴生津;润肺清心。主治肺燥干咳,阴虚痨嗽,喉痹咽痛,津伤口渴,内热消渴,心烦失眠,肠燥便秘。《名医别录》载:“麦冬疗身重目黄,心下支满,虚劳客热,口干烦渴,止呕吐,愈痿蹶,强阴益精,消谷调中,保神,定肺气,安五脏,令人肥健。”现代医学研究证实,麦冬含有多种甾体皂甙、胡萝卜素、粘液质、糖类、豆甾醇等成分,有升高白细胞,延长抗体存在时间的作用,同时提高免疫功能和核酸合成率,促进抗体、补体、干扰素、溶菌酶等免疫物质的产生,有增强正气、加强抗邪作用。
金钱草:味甘;微苦;性凉。入肝;胆;肾;膀胱经。利水通淋;清热解毒;散瘀消肿。主治肝胆及泌尿系结石;热淋;肾炎水肿;湿热黄疸;疮毒痈肿;毒蛇咬伤;跌打损伤。现代医学研究证实,金钱草主要含酚性成分和甾醇、黄酮类、鞣质、挥发油、胆碱、钾盐等,具有排石、抑菌、通淋、抗炎作用,对体液免疫、细胞免疫均有明显的抑制作用。
墨旱莲:味甘;酸;性凉。归肝;肾经。补益肝肾;凉血止血。主治:肝肾不足;头晕目眩;须发早白;吐血;咯血;衄血;便血;血痢;崩;漏;外伤出血。《分类草药性》:止血,补肾,退火,消肿。治淋、崩。
响铃草:味苦微酸;性平寒。归肺经。滋肾养肝,止咳平喘,利湿解毒。主治耳鸣,耳聋,头目眩晕,遗精,月经过多,白带,久咳痰血,哮喘,肾炎,小便不利,扁桃体炎,腮腺炎,疔疮肿毒。.《草木便方》:补中益气,疗耳鸣,头目昏眩,崩淋。又泻火清热,平肝风,消肿痛。
石斛:味甘;性微寒。归胃;肺;肾经。生津益胃;滋阴清热;润肺益肾;明目强腰。主治热病伤津;口干烦渴;胃阴不足;胃痛干呕;肺燥干咳;虚热不退;阴伤目蝉;腰膝软弱。《本草正》载:“石斛益精强阴,壮筋补虚,健脚膝,驱冷痹,却惊悸,定心志,有从容分解之妙,故能退火、养阴、除烦、清肺下气,亦止消渴热汗。”现代医学研究证实,石斛能显著增强巨噬细胞的吞噬作用,能抑制考的松或环磷酰胺所致的免疫,有显著的免疫激活作用,对环磷酰胺所致的白细胞下降有保护作用,并能明显提高鼻咽癌患者NK细胞的活性,能促进唾液、胃液、肠液分泌,能扩张微血管,增加血流,增强心肌收缩力,此外还有解热、镇痛等作用。
三白草:味苦;辛;性寒。归肺;脾;胃;大肠经。清热利水;解毒消肿。主治热淋;血淋;水肿;脚气;黄疸;痢疾;带下;痈肿疮毒;湿疹;蛇咬伤。《岭南采药录》:治淋浊,利小便,消热毒。
山萸肉:味酸;性微温,归肝;肾经。补益肝肾;收敛固脱,主治:腰头晕目眩;耳聋耳鸣;腰膝酸软;跹精滑精;小便频数;虚汗不止;妇女崩漏。《医学入门》:山茱萸本涩剂也,何以能通发邪?盖诸病皆系下部虚寒,用之补养肝肾,以益其源,则五脏安利,闭者通而利者止,非若他药轻飘疏通之谓也。现代医学研究表明:山萸肉具有抗菌、调节免疫、降血糖、降血脂、抗氧化、抗癌、抗艾滋病、强心等功能。
车前草:味甘;性寒。归肝;肾;膀胱经。清热利尿;凉血;解毒。主治:热结膀胱;小便不利;淋浊带下;暑湿泻痢;衄血;尿血;肝热目赤;咽喉肿痛;痈肿疮毒。现代药理试验结果表明,车前草煎剂具有祛痰镇咳、抗真菌的作用。
石韦:味甘;苦;性平;微寒。入肺;膀胱经。利水通淋;清肺泄热;主治淋痛;尿血;尿路结石;肾炎;崩漏;痢疾;肺热咳嗽;慢性气管炎;金疮;痈疽。《纲目》载:“主崩漏,金疮,清肺气。”现代医学研究证实,石韦对金黄色葡萄球菌、变形杆菌、大肠杆菌有不同程度的抑制作用,抗流感病毒,有效提升白细胞数量,多适用于治疗热淋,有清热止血之功效。
斑叶兰:味甘;辛;性平。润肺止咳;补肾益气;行气活血;消肿解毒。主治肺痨咳嗽;气管炎;头晕乏力;神经衰弱;阳痿;跌打损伤;骨节疼痛;咽喉肿痛;疮疖;瘰疬;毒蛇咬伤。《西藏常用中草药》:"软坚散结。治瘰疬。"
木通根:味苦;性平;归肝;肾经。祛风通络;利水消肿;行气活血;补肝肾;强筋骨。主治风湿痹痛;跌打损伤;经闭;疝气;睾丸肿痛;脘腹胀闷;小便不利;带下;虫蛇咬伤。《浙江民间常用草药》:祛风止痛,行气活血,利尿解毒。
黑芝麻:味甘;性平。归肝;脾;肾经。补益肝肾;养血益精;润肠通便。用于头晕眼花,耳鸣耳聋,须发早白,病后脱发,肠燥便秘。现代医学研究证明:黑芝麻具有降血糖作用、促肾上腺作用、抗炎作用及对心血管有一定作用。
川芎:味辛;性温。归肝;胆;心包经。活血祛瘀;行气开郁;祛风止痛。主治癓瘕肿块;胸胁疼痛;头痛眩晕;风寒湿痹;跌打损伤;痈疽疮疡。《本草正》载:“散风寒,治痛,破瘀蓄,通血脉,解结气,逐疼痛,排脓消肿,逐血通经。”现代医学科学研究发现,川芎提取液对抑制白血病细胞有一定作用,制剂有一定的抗菌作用,尤其是对伤寒杆菌、副伤寒杆菌、霍乱弧菌、绿脓杆菌及致病性皮肤真菌等均有抑制作用,川芎所含的川芎嗪、阿魏酸纳具有活血化瘀功效,可扩张冠状动脉,增进冠脉流量,缓解心绞痛,并具有抗血栓形成作用,所含的川芎内酯有平滑肌解痉和抑制肠肌、子宫收缩等作用。
金丝梅:味苦;性寒。归肝;肾;膀胱经。清热利湿解毒;疏肝通络;祛瘀止痛。主治湿热淋病;肝炎;感冒;扁桃体炎;疝气偏坠;筋骨疼痛;跌打损伤。
决明子:味咸;苦;性平;凉;无毒。入肝;胆;肾经。祛风清热;解毒利湿。主治风热感冒;流感;急性结膜炎;湿热黄疸;急慢性肾炎;带下;瘰疬;疮痈疖肿;乳腺炎。《日华子本草》载:“助肝气,益精水,消肿毒,搽太阳穴治头痛,贴脑心止鼻衄,治头风,明目。”现代医学研究证实,决明子的醇提物对葡萄球菌、白喉杆菌、伤寒、副伤寒、大肠杆菌均有抵制作用,对石膏样毛癣菌、许兰黄癣菌、奥杜盎小芽胞癣菌等真菌有不同程度的抑制作用,能显著降低舒张压,升高血清高密度脂蛋白-胆固醇含量和HDL-C/TC比值,改善体内胆固醇的分布状况,增强免疫功能,此外还有保肝和泻下作用。
女贞子:味苦;性凉。归肝;肾经。补肝肾阴,乌须明目。主治肝肾阴虚;腰酸耳鸣;须发早白;眼目昏暗;阴虚发热;胃病及痛风和高尿酸血症。《本草再新》:养阴益肾,补气舒肝。治腰腿疼,通经和血。现代医学研究证明,女贞子含齐墩果酸、甘露酸、葡萄酸、棕榈酸、硬脂酸、油酸、亚油酸等。女贞子能提高外周白细胞、增强网状内皮系统吞噬能力,有增强细胞免疫和体液免疫的作用,又有降血脂、抗动脉粥样硬化的作用,对因化疗或放疗引起的白细胞减少有升高作用,能抑制动物某些移植性肿瘤的生长,并有强心、利尿、保肝、止咳、缓泻、抗菌等作用。
甘草:味甘;性平。归心;肺;脾;胃经。补脾益气;清热解毒;祛痰止咳;缓急止痛;调和诸药。主治脾胃虚弱;倦怠乏力;心悸气短;咳嗽痰多;脘腹四脚挛急疼痛;痈肿疮毒;缓解药物毒性。《本草纲目》载:“诸药中甘草为君。治七十二种乳石毒,解一千二百般草本毒,调和从药有功。”现代医学研究证实,甘草有较强的解毒作用,还有抗溃疡、抗炎症、镇痉镇咳、降血压、降血脂、抗癌作用,广泛用于治疗咽喉炎、喉炎、气管炎、支气管炎、哮喘、咳嗽、咳血等疾病,此外还具有抗胃溃疡、抗胃炎作用。
山莴笋:味苦;性寒。清热解毒利湿。主治肺热咳嗽;湿热黄疸;肠胃炎;湿热水肿;头痛;痛经;白带等。
五味子:味辛;苦;性温。收敛固涩;益气生津;补肾宁心;祛风利湿;理气活血。主治风湿骨痛;跌打损伤;胃痛;月经不调;肾炎。《本经》载:“主益气,咳逆上气,劳伤羸度,补不足,强阴。”现代医学研究证实,五味子含有丰富的有机酸、维生素、类黄酮、植物固醇及有强效复原作用的木酚素,它也是兼具精、气、神三大补益的少数药材之一,能益气强肝、增进细胞排除废物的效率、供应更多氧气、营造和运用能量、提高记忆力及性持久力。
本发明与现有技术相比,具有以下有益效果:
本发明选用药材的药性相适相辅,针对病因对症下药,有补益肝肾、养阴益气、行气活血、清热利湿、解毒消肿之功效,标本兼治,可调节机体免疫,改善肝肾功能,吸收效果好,疗效显著,无毒副作用及临床不良反应,经临床验证对肝肾阴虚型慢性肾盂肾炎治愈率较高。
具体实施方式
下面结合具体实施例对本发明做进一步阐述。
实施例1
本发明药物有效成分的原料组成及重量为:
本发明药物制备方法的工艺步骤为:
(1)将凤尾草、黄精、白紫草、石莽草、麦冬、墨旱莲、响铃草、石斛、三白草、山萸肉、车前草、石韦、黑芝麻、金丝梅、女贞子、山莴笋洗净、晾干后混合均匀,放入容器中,在容器中加入6~8倍量的水,加热煮沸2~3小时,冷却后取浸液;在剩余的药渣中再加入4~6倍量的水,加热煮沸1~2小时,冷却后取浸液;合并两次所得浸液,加热,蒸发浓缩为相对密度1.15~1.25的稠膏,备用;
(2)将枸骨叶、金钱草、斑叶兰、木通根放入容器中,加入3~5倍量的绍兴黄酒,煮沸后放凉,继续浸泡3~5小时,取浸液;在剩余的药渣中再加入2~4倍量的绍兴黄酒,煮沸后放晾,继续浸泡2~4小时,取浸液;合并两次所得浸液,加蒸蒸发浓缩为相对密度1.10~1.20的稠膏,备用;
(3)取川芎片用黄酒喷洒均匀,稍闷,置锅内炒至微焦为度,取出放凉,粉碎研末,过100目细筛,得细粉,备用;
(4)取净决明子,置锅内炒至微有香气,取出,放凉,粉碎研末,过100目细筛,得细粉,备用;
(5)取净甘草片,加入炼熟的蜂蜜与少许开水,拌匀后稍闷,置炒制容器内,文火炒至黄色至深黄色,不粘手时取出,放凉,粉碎研末,过100目细筛,得细粉,备用;
(6)将五味子粉碎后研末,过100目细筛,得细粉,备用;
(7)将步骤(1)、步骤(2)所得的稠膏,与步骤(3)、步骤(4)、步骤(5)、步骤(6)中所得的细粉混合,加入炼蜜搅拌均匀后,制备为每粒3g的药丸。
用法用量:口服,每日2次每次2粒,饭前一小时以温开水送服,15天为1个疗程。
实施例2
本发明药物有效成分的原料组成及重量为:
本实施例的药物制备方法工艺步骤及用法用量与实施例1相同。
实施例3
本发明药物有效成分的原料组成及重量为:
临床资料:
1、病例选择
选择我院确诊的肝肾阴虚型慢性肾盂肾炎患者74例临床观察,病人随机分成两组。治疗组37例,其中男性14例,女性23例,年龄22~59岁,平均年龄45.6岁,病程最短者1个月,最长者2年,平均0.8年。对照组37例,其中男性12例,女性25例,年龄21~57岁,平均年龄44.3岁,病程最短者1个月,最长者2.1年,平均0.9年。两组资历基本一致,无显著差异,具有可比性。
2、治疗组患者服用本发明药物,口服,每日2次每次2粒,饭前一小时以温开水送服,15天为1个疗程,服用3个疗程。对照组根据诊断出的慢性肾盂肾炎的症状,对症予以抗生素类药物进行抗菌消炎治疗。
3、疗效判定:
(1)治愈:临床症状完全消失,尿常规检查正常,尿菌阴性,随访6个月无复发。
(2)好转:临床症状明显减轻,尿常规检查接近正常,尿菌阴性。
(3)无效:症状同施治前无明显差异。
4、结果
治疗组中治愈23例,好转11例,无效3例,治愈率62.2%,总有效率91.9%。
对照组中治愈19例,好转13例,无效5例,治愈率51.4%,总有效率86.5%。
以上结果显示,治疗组的治愈率和总有效率明显高于对照组。
典型病例举例:
1、孙××,女,45岁。该患者曾做胆囊手术,因插导尿管引起尿路感染,后偶有发作,近几个月因工作加班多,身体劳累,时常出现尿频、尿急、尿道灼热、头晕、腰酸等症状,使用抗生素进行治疗缓解,但近两周上述症状又时有复发,来院检查,确诊为肝肾阴虚型慢性肾盂肾炎,经服用本发明中药3个疗程后,上述症状完全消失,尿常规检查正常,尿菌阴性,后随访6个月无复发,已痊愈。
2、何××,女,58岁。患者近半年来有口干唇燥、失眠多梦、腰膝酸软、手足心热等症状,其舌红少全苔,脉沉细,诊断为肝肾阴虚型慢性肾盂肾炎,经服用本发明中药3个疗程后,上述症状完消失,尿常规检查正常,尿菌阴性,后随访6个月无复发,已痊愈。
由于慢性肾盂肾炎易反复发作,肾脏炎症和修复过程交替进行,结缔组织增生和瘢痕形成,局部血运差,抗生素不易进入病灶,常需加大抗生素用量,但抗生素治疗虽可暂时缓解症状,但常不彻底,易复发,治疗效果不理想。本发明中药根据病因对症下药,方中女贞子、枸骨叶、山萸肉、黑芝麻、墨旱莲、响铃草可补益肝肾;方中五味子、斑叶兰、木通根、川芎、黄精可补肾益气、行气活血;方中黄精、麦冬、石斛、白紫草可清热养阴;方中三白草、山莴笋、金丝梅、决明子、石韦、凤尾草、石莽草、车前草、金钱草等中药可清热利湿、利水通淋、解毒消肿;方中甘草可调和诸药;方中诸药合用,共奏补益肝肾、养阴益气、行气活血、清热利湿、解毒消肿之功效,标本兼治,可调节机体免疫,改善肝肾功能,吸收效果好,疗效显著,无毒副作用及临床不良反应,经临床验证对肝肾阴虚型慢性肾盂肾炎治愈率较高。
Claims (4)
1.一种用于肾阴虚型慢性肾盂肾炎的中药丸剂,其特征在于:制成所述药物有效成分的原料组成及重量份数为:
凤尾草70~88份黄精66~86份枸骨叶62~82份白紫草58~78份
石莽草55~74份麦冬52~70份金钱草50~68份墨旱莲46~65份
响铃草43~61份石斛40~57份三白草37~53份山萸肉35~50份
车前草32~47份石韦29~44份斑叶兰26~40份木通根23~37份
黑芝麻20~33份川芎18~30份金丝梅15~26份决明子12~23份
女贞子9~20份甘草6~16份山莴笋4~12份五味子2~9份。
2.根据权利要求1所述的一种用于肾阴虚型慢性肾盂肾炎的中药丸剂,其特征在于:制成所述药物有效成分的原料组成及重量份数为:
凤尾草74~85份黄精70~82份枸骨叶65~78份白紫草62~75份
石莽草58~70份麦冬55~67份金钱草53~65份墨旱莲50~62份
响铃草46~58份石斛43~53份三白草40~50份山萸肉38~46份
车前草35~43份石韦32~40份斑叶兰30~37份木通根26~34份
黑芝麻23~30份川芎20~26份金丝梅18~23份决明子15~20份
女贞子11~17份甘草8~14份山莴笋5~10份五味子3~7份。
3.根据权利要求1所述的一种用于肾阴虚型慢性肾盂肾炎的中药丸剂,其特征在于:制成所述药物有效成分的原料组成及重量份数为:
凤尾草80份黄精76份枸骨叶72份白紫草69份
石莽草65份麦冬62份金钱草59份墨旱莲56份
响铃草52份石斛48份三白草45份山萸肉42份
车前草39份石韦36份斑叶兰33份木通根30份
黑芝麻27份川芎23份金丝梅20份决明子17份
女贞子14份甘草11份山莴笋8份五味子5份。
4.一种用于肾阴虚型慢性肾盂肾炎的中药丸剂的制备方法,其特征在于:包括以下工艺步骤:
(1)将凤尾草、黄精、白紫草、石莽草、麦冬、墨旱莲、响铃草、石斛、三白草、山萸肉、车前草、石韦、黑芝麻、金丝梅、女贞子、山莴笋洗净、晾干后混合均匀,放入容器中,在容器中加入6~8倍量的水,加热煮沸2~3小时,冷却后取浸液;在剩余的药渣中再加入4~6倍量的水,加热煮沸1~2小时,冷却后取浸液;合并两次所得浸液,加热,蒸发浓缩为相对密度1.15~1.25的稠膏,备用;
(2)将枸骨叶、金钱草、斑叶兰、木通根放入容器中,加入3~5倍量的绍兴黄酒,煮沸后放凉,继续浸泡3~5小时,取浸液;在剩余的药渣中再加入2~4倍量的绍兴黄酒,煮沸后放晾,继续浸泡2~4小时,取浸液;合并两次所得浸液,加蒸蒸发浓缩为相对密度1.10~1.20的稠膏,备用;
(3)取川芎片用黄酒喷洒均匀,稍闷,置锅内炒至微焦为度,取出放凉,粉碎研末,过100目细筛,得细粉,备用;
(4)取净决明子,置锅内炒至微有香气,取出,放凉,粉碎研末,过100目细筛,得细粉,备用;
(5)取净甘草片,加入炼熟的蜂蜜与少许开水,拌匀后稍闷,置炒制容器内,文火炒至黄色至深黄色,不粘手时取出,放凉,粉碎研末,过100目细筛,得细粉,备用;
(6)将五味子粉碎后研末,过100目细筛,得细粉,备用;
(7)将步骤(1)、步骤(2)所得的稠膏,与步骤(3)、步骤(4)、步骤(5)、步骤(6)中所得的细粉混合,加入炼蜜搅拌均匀后,制备为每粒3g的药丸。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510814981.8A CN105267696A (zh) | 2015-11-23 | 2015-11-23 | 一种用于肾阴虚型慢性肾盂肾炎的中药丸剂及制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510814981.8A CN105267696A (zh) | 2015-11-23 | 2015-11-23 | 一种用于肾阴虚型慢性肾盂肾炎的中药丸剂及制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105267696A true CN105267696A (zh) | 2016-01-27 |
Family
ID=55138086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510814981.8A Pending CN105267696A (zh) | 2015-11-23 | 2015-11-23 | 一种用于肾阴虚型慢性肾盂肾炎的中药丸剂及制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105267696A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796682A (zh) * | 2016-05-16 | 2016-07-27 | 杨莉 | 一种治疗肝肾阴亏型慢性肾小球肾炎的中药组合物 |
| CN116784473A (zh) * | 2022-05-19 | 2023-09-22 | 沈启良 | 一种新型功能性食品及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101234146A (zh) * | 2008-02-29 | 2008-08-06 | 贵阳华芝宝生物研究科技有限公司 | 治疗泌尿系统感染的中药制剂及其制备方法 |
| CN103156925A (zh) * | 2011-12-19 | 2013-06-19 | 赖泽洪 | 一种治疗肾盂肾炎的药物 |
| KR20130109495A (ko) * | 2012-03-27 | 2013-10-08 | 한국과학기술연구원 | 석곡을 포함하는 신장 질환의 예방 또는 치료용 조성물 |
-
2015
- 2015-11-23 CN CN201510814981.8A patent/CN105267696A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101234146A (zh) * | 2008-02-29 | 2008-08-06 | 贵阳华芝宝生物研究科技有限公司 | 治疗泌尿系统感染的中药制剂及其制备方法 |
| CN103156925A (zh) * | 2011-12-19 | 2013-06-19 | 赖泽洪 | 一种治疗肾盂肾炎的药物 |
| KR20130109495A (ko) * | 2012-03-27 | 2013-10-08 | 한국과학기술연구원 | 석곡을 포함하는 신장 질환의 예방 또는 치료용 조성물 |
Non-Patent Citations (3)
| Title |
|---|
| 李顺民等: "芪地五神汤治疗肾虚湿热型慢性肾盂肾炎48例疗效观察", 《新中医》 * |
| 杨明等: "《药剂学》", 31 August 2014 * |
| 赵毅鹏等: "《疑难病诊疗学》", 30 September 1998 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796682A (zh) * | 2016-05-16 | 2016-07-27 | 杨莉 | 一种治疗肝肾阴亏型慢性肾小球肾炎的中药组合物 |
| CN116784473A (zh) * | 2022-05-19 | 2023-09-22 | 沈启良 | 一种新型功能性食品及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104187172B (zh) | 用于治疗乌龟肠胃炎病的功能性饲料及其制备方法 | |
| CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN103933509B (zh) | 用于治疗淡水鱼水霉病的药物及其制备方法 | |
| CN103536778B (zh) | 一种治疗偏头痛的中药制剂 | |
| CN103316146A (zh) | 一种麻醉用中药制剂 | |
| CN104069474A (zh) | 一种治疗脂溢性脱发的中药组合物及其制备方法 | |
| CN103520655A (zh) | 一种治疗寻常型银屑病的中药组合物及其制备方法 | |
| CN105148039A (zh) | 一种用于缓解肿瘤放疗后反应的中药药丸及制备方法 | |
| CN103041257B (zh) | 治疗小儿发热高烧呼吸道感染的中药制剂 | |
| CN105535371A (zh) | 一种治疗膝关节滑膜炎的中药 | |
| CN104771729A (zh) | 一种用于肺癌辅助治疗的中药丸剂及制备方法 | |
| CN103652450B (zh) | 一种猪饲料及其制备方法 | |
| CN103611021B (zh) | 用于治疗猪膀胱炎的药物及其制备方法 | |
| CN106822585A (zh) | 具有滋阴壮阳、补中益气的中药保健制剂及其制备方法 | |
| CN105267696A (zh) | 一种用于肾阴虚型慢性肾盂肾炎的中药丸剂及制备方法 | |
| CN103041255B (zh) | 治疗小儿咽喉肿痛呼吸道感染的中药制剂 | |
| CN104873926A (zh) | 治疗腹泻的中药制剂及其制备方法与应用 | |
| CN104189413A (zh) | 用于治疗乌龟肠胃炎病的药物组合物及其制备方法 | |
| CN103656048A (zh) | 用于治疗奶牛乳房炎的药物及其制备方法 | |
| CN104398873B (zh) | 一种用于外痔的中药制剂及其制备方法 | |
| CN105456661A (zh) | 一种用于治疗放射性皮炎的中药冲剂及制备方法 | |
| CN104524422A (zh) | 一种治疗男性乳房发育症的药丸及制备方法 | |
| CN105213999A (zh) | 一种温经止痛的丹参叶保健茶及其制备方法 | |
| CN103977279A (zh) | 一种治疗母猪子宫炎的中药添加剂及其制备方法 | |
| CN104083548A (zh) | 一种治疗卵巢囊肿的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160127 |